Alphabet Class A (GOOGL) Receives a Hold from UBS
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ju covers the Communication Services sector, focusing on stocks such as Alphabet Class A, Meta Platforms, and Alphabet Class C. According to TipRanks, Ju has an average return of 13.0% and a 52.87% success rate on recommended stocks.
In addition to UBS, Alphabet Class A also received a Hold from Wells Fargo's Ken Gawrelski in a report issued yesterday. However, on the same day, Needham maintained a Buy rating on Alphabet Class A (NASDAQ: GOOGL).
Based on Alphabet Class A's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $96.43 billion and a net profit of $28.2 billion. In comparison, last year the company earned a revenue of $84.74 billion and had a net profit of $23.62 billion
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Philippe Laffont Loads Up on Oracle, ARM--Cuts AMD, Alibaba, Eli Lilly Stakes
Aug 15 - Philippe Laffont (Trades, Portfolio)'s Coatue shook up its Q2 portfolio, loading into Oracle (ORCL) and ARM (NASDAQ:ARM) while exiting Super Micro (NASDAQ:SMCI) and Monolithic Power (MPWR). The firm bought roughly 3.86 million Oracle shares (about $843.3M) and 4.63 million ARM shares ($749.4M), according to its latest 13F filing, signaling renewed conviction in large-cap cloud and chip plays. Warning! GuruFocus has detected 3 Warning Sign with SMCI. Coatue also increased its stake in CoreWeave (NASDAQ:CRWV) to about 17.8M shares (~$2.9B) and added to positions in Broadcom (AVG) and Nvidia (NASDAQ:NVDA), reflecting a clear tilt toward AI infrastructure. At the same time the hedge fund trimmed holdings in Alibaba (NYSE:BABA), AMD (NASDAQ:AMD) and Eli Lilly (NYSE:LLY), and sold out of Monolithic Power and Super Micro. The moves indicate a change in strategy: strengthen names sensitive to AI compute and cloud capacity and reduce cyclical or less strategic exposure. For investors, the swaps of Coatue are of importance since their bet of more than $0.8B on Oracle reflects its conviction on cloud and software momentum. See what happens to the rest of the large funds; action across the AI related names can exaggerate moves, either upwards when new demand shines through or down when the mood swings. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 minutes ago
- Business Wire
ProShares Launches First ETF to Target 2x Daily Returns of Nasdaq-100 Top 30 Index
BETHESDA, Md.--(BUSINESS WIRE)--ProShares, the world's leader in leveraged and inverse ETFs, today announced the launch of ProShares Ultra QQQ Top 30 (QQXL) —the first and only ETF designed to target 2x the daily returns of the Nasdaq-100 Top 30 Index. QQXL expands ProShares' $40 billion suite of leveraged and inverse ETFs linked to the Nasdaq-100, which includes ProShares UltraPro QQQ (TQQQ), the world's largest leveraged ETF. 1 The Nasdaq-100 Top 30 Index offers focused exposure to 30 of the largest and most influential companies in the tech-heavy Nasdaq-100. The index features leaders like Nvidia, Apple, Meta Platforms, and Palantir—firms driving innovation on a global scale. 2 'In recent years, market leadership has converged around a group of innovators—many in technology—who are redefining what's possible, a trend that investors are eager to capture,' said ProShares CEO Michael L. Sapir. 'With QQXL, investors can now target 2x the daily returns of these market leaders with the ease and convenience of a single ETF trade.' ProShares pioneered the leveraged and inverse ETF category nearly two decades ago and remains the largest provider in the world, 3 offering funds linked to major stock indexes, single stocks, fixed income, commodities, currencies, cryptocurrencies, and volatility. About ProShares ProShares has been at the forefront of the ETF revolution since 2006. ProShares manages over $90 billion in assets and offers one of the largest lineups of ETFs. 4 The company is a leader in strategies such as dividend growth, high income, interest rate hedged bond, crypto-linked and geared (leveraged and inverse) ETF investing. ProShares continues to innovate with products that provide strategic and tactical opportunities for investors to manage risk and enhance returns. Geared ProShares ETFs seek daily investment results that correspond, before fees and expenses, to a multiple of (e.g., 2x or -2x) the daily performance of its underlying benchmark (the 'Daily Target'). While the Funds have a daily investment objective, you may hold Fund shares for longer than one day if you believe it is consistent with your goals and risk tolerance. For any holding period other than a day, your return may be higher or lower than the Daily Target. These differences may be significant. Smaller index gains/losses and higher index volatility contribute to returns worse than the Daily Target. Larger index gains/losses and lower index volatility contribute to returns better than the Daily Target. The more extreme these factors are, the more they occur together, and the longer your holding period while these factors apply, the more your return will tend to deviate. Investors should consider periodically monitoring their geared fund investments in light of their goals and risk tolerance. Investing involves risk, including the possible loss of principal. Leveraged ProShares ETFs are non-diversified and entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance, all of which can increase volatility and decrease performance. The ETF may concentrate its investments in certain sectors. Narrowly focused investments typically exhibit higher volatility. Technology companies may experience intense competition, obsolescence of existing technology, changing economic conditions, and government regulation. Investors could potentially lose the full value of their investment within a single day. Please see the summary and full prospectuses at for a more complete description of risks. There is no guarantee any ProShares ETF will achieve its investment objective. Shares of any ETF are generally bought and sold at market price (not NAV) and are not individually redeemed from the fund. Your brokerage commissions will reduce returns. Carefully consider the investment objectives, risks, charges and expenses of ProShares before investing. This and other information can be found in their summary and full prospectuses at Read them carefully before investing. ProShares are distributed by SEI Investments Distribution Co., which is not affiliated with the funds' advisor or sponsor. 'QQQ®,' 'Nasdaq-100 Index®,' 'Nasdaq-100®' and 'Nasdaq-100 Top 30 Index' are registered trademarks of The Nasdaq OMX Group Inc. and have been licensed for use by ProShares. This ETF is not sponsored, endorsed, sold or promoted by The Nasdaq OMX Group Inc. and The Nasdaq OMX Group Inc. makes no representation regarding the advisability of investing in this ETF. THE Nasdaq OMX GROUP INC. MAKES NO WARRANTIES AND BEARS NO LIABILITY WITH RESPECT TO THE ETFs.
Business Wire
6 minutes ago
- Business Wire
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure. BARDA's mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI's mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government's expressed interest to engage and fund advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. 'It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,' said Handley. Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field. About MHSRS MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible. About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
